Lucentis treats vein occlusion

Anti-angiogenic drug Lucentis has been shown to be of benefit in the management of ischaemic central retinal vein occlusion.

The drug, used widely in the management of wet AMD, helps reduce neovascularisation, a known complication of ischaemic retinal diseases such as in some vein occlusions. A study, published in this month's Ophthalmology, shows how nine out of 10 subjects reported stabilisation or improvement in acuity with bimonthly injections of Lucentis, although any therapeutic effect lapsed within three months of cessation of treatment.